First-line latanoprost therapy in ocular hypertension or open-angle glaucoma patients: a 3-month efficacy analysis stratified by initial intraocular pressure

BMC Ophthalmology

Research Article

Mourad Amrane¹  Eric Sellem²  Jean-Philippe Nordmann³  Christophe Baudouin⁴  Philippe Denis⁵  Alain Bron⁶  Jean François Rouland⁷  Jean Paul Renard⁸ 

[1] 1 allée Giuseppe Verdi, 94350, Villiers Sur Marne, France;Centre Ophtalmologique Kléber, 50, Cours Franklin Roosevelt, 69006, Lyon, France;Ophthalmology Department 2, Centre Hospitalier National des Quinze-Vingts, 28, Rue de Charenton, Paris Cedex 12, France;Ophthalmology Department 3, Centre Hospitalier National des Quinze-Vingts, 28, Rue de Charenton, Paris Cedex 12, France;Ophthalmology Department, Hôpital Edouard Herriot, 5, Place d'Arsonval, 690437, Lyon Cedex 03, France;Ophthalmology Department, Hôpital Général, 3, Rue du Faubourg Raines, 21033, Dijon, France;Ophthalmology Department, Hôpital Huriez, 1, 59037, Place de Verdun, Lille, France;Ophthalmology Department, Hôpital d'Instruction des Armées du Val de Grâce, 74, Boulevard du Port Royal, Paris Cedex 05, France;

关键词: Latanoprost;    Ocular Hypertension;    Bimatoprost;    Multiple Correspondence Analysis;    Travoprost;   

DOI  :  10.1186/1471-2415-10-4

 received in 2009-09-09, accepted in 2010-02-24,  发布年份 2010

来源: Springer

【 摘 要 】

BackgroundProspective, multicenter, randomized, double-masked trials have shown latanoprost instilled once daily to be at least as effective as and generally superior to timolol administered twice daily and to be as effective as other frequently prescribed prostaglandin analogues. This study prospectively assessed the efficacy of latanoprost monotherapy in a large cohort of treatment-naive patients with a broad range of baseline intraocular pressure (IOP) levels treated in actual clinical practice settings.MethodsThis prospective, open-label, multicenter, uncontrolled, phase IV study included treatment-naive ocular hypertension or open-angle glaucoma subjects initiating latanoprost once daily (evening). IOP levels were measured at baseline and after 1 and 3 months. The primary efficacy outcome was mean change in IOP from baseline to month 3. Analyses were stratified by baseline IOP: ≥ 20 and <24 mmHg vs ≥ 24 mmHg.ResultsEfficacy analyses (intent to treat) included 572 subjects: 20 to <24 mmHg group, N = 252; ≥ 24 mmHg group, N = 320. Mean baseline IOP levels were 22.2 ± 0.9 mmHg and 26.7 ± 2.8 mmHg, respectively. At month 3, significant IOP reductions were seen in both groups (p < 0.0001, within-group differences); reductions were smaller in the 20 to <24 mmHg group (-6.3 ± 2.4 vs -9.2 ± 3.7 mmHg, respectively; -28.0 ± 10.6% vs -34.1 ± 11.9%, respectively). An IOP reduction of ≥ 30% from baseline to month 3 was noted in 48.4% and 65.6% of subjects, respectively (p < 0.0001). At month 3, targets IOPs of ≤ 18 mmHg were achieved by ≥ 70% of subjects in both groups. Latanoprost was well tolerated with an adverse event profile similar to that reported in the literature.ConclusionsThis "real world" study found once-daily latanoprost to be effective and safe in treatment-naive ocular hypertension or open-angle glaucoma patients. Patients with baseline IOP levels of 20 to <24 mmHg as well as ≥ 24 mmHg benefitted from initial latanoprost therapy.Trial RegistrationTrial Registration Number: NCT00647101

【 授权许可】

CC BY   
© Denis et al; licensee BioMed Central Ltd. 2010